- Mesoblast (MESO, Financial) expands Ryoncil coverage to 104 million US lives.
- 80% of Medicaid fee-for-service lives now covered in 37 states.
- Commercial plans provide coverage for 84 million lives.
Mesoblast (MESO) has successfully extended insurance coverage for its FDA-approved therapy, Ryoncil® (remestemcel-L), to reach over 104 million lives in the United States. This significant milestone includes coverage from both government and commercial payers.
Ryoncil®, the first FDA-approved mesenchymal stromal cell (MSC) treatment, has achieved notable coverage through Medicaid. Currently, 37 of 51 states offer fee-for-service Medicaid coverage via Orphan Drug Lists or a medical exception/prior authorization process, encompassing approximately 20 million lives, or 80% of the total Medicaid fee-for-service population. The remaining states are set to implement mandatory coverage for an additional 24 million lives by July 1, 2025.
Furthermore, commercial insurance plans, along with managed Medicaid, have established policies that cover 84 million lives. These figures do not include coverage through Medical Exceptions policies, suggesting the actual total coverage might be higher than reported.
Mesoblast remains committed to expanding its proprietary mesenchymal lineage cell therapy technology platform to develop therapies for severe inflammatory conditions. In addition to Ryoncil®, the company is working on new treatments for conditions such as steroid-refractory acute graft versus host disease (SR-aGvHD) in adults and biologic-resistant inflammatory bowel disease.
